Cargando…

Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women

The predictive role of tumour proliferative rate and expression of p53, bcl-2 and bax proteins, alone and in association with tumour size, nodal involvement and oestrogen receptors (ER), was analysed on 145 elderly patients (≥70 years of age) with histologically assessed node-positive breast cancers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daidone, M G, Luisi, A, Martelli, G, Benini, E, Veneroni, S, Tomasic, G, De Palo, G, Silvestrini, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363285/ https://www.ncbi.nlm.nih.gov/pubmed/10646876 http://dx.doi.org/10.1054/bjoc.1999.0914

Ejemplares similares

Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen
por: Coradini, D, et al.
Publicado: (2003)

Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer
por: Coradini, D, et al.
Publicado: (2001)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Long-term follow-up of elderly patients with operable breast cancer treated with surgery without axillary dissection plus adjuvant tamoxifen.
por: Martelli, G., et al.
Publicado: (1995)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Expression of high-affinity 67-kDa laminin receptors in primary breast cancers and metachronous metastatic lesions or contralateral cancers.
por: Daidone, M. G., et al.
Publicado: (1997)

Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania
por: Trinconi, Cristiana T., et al.
Publicado: (2018)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence
por: Coradini, D, et al.
Publicado: (2002)

Development and characterization of a tamoxifen-resistant breast carcinoma xenograft
por: Naundorf, H, et al.
Publicado: (2000)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999)

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
por: Marttunen, M B, et al.
Publicado: (2001)

Involvement of bcl-2 and p21(waf1) proteins in response of human breast cancer cell clones to Tomudex
por: Orlandi, L, et al.
Publicado: (1999)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines
por: Ferlini, C, et al.
Publicado: (1999)

Modelling the effects of standard prognostic factors in node-positive breast cancer
por: Sauerbrei, W, et al.
Publicado: (1999)

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
por: Loi, Sherene, et al.
Publicado: (2008)

Impact of biospecimens handling on biomarker research in breast cancer
por: De Cecco, Loris, et al.
Publicado: (2009)

Identification of women with early breast cancer by analysis of p43-positive lymphocytes
por: Auerbach, L, et al.
Publicado: (1999)

Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up
por: Martelli, Gabriele, et al.
Publicado: (2010)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line
por: Parisot, J P, et al.
Publicado: (1999)

Histiocytic lymphoma of breast responds to tamoxifen.
por: Millis, R. R., et al.
Publicado: (1988)

Application of an original RT-PCR–ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients
por: Ferrero, J M, et al.
Publicado: (2000)

Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation
por: Hirata, Kimiko, et al.
Publicado: (2017)

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
por: Poikonen, P, et al.
Publicado: (1999)

Tamoxifen for women at high risk of breast cancer
por: Nazarali, Safia A, et al.
Publicado: (2014)

First do no harm: extending the debate on the provision of preventive tamoxifen
por: Will, B P, et al.
Publicado: (2001)

Adjuvant chemotherapy for colon carcinoma with positive lymph nodes: use and benefit in routine health care practice
por: Bouchardy, C, et al.
Publicado: (2001)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Effects of treatment with chemotherapy and/or tamoxifen on the biomarkers of cardiac injury and oxidative stress in women with breast cancer
por: Silva, Fabricio Bragança, et al.
Publicado: (2017)

Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
por: Park, Y, et al.
Publicado: (2009)

Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy
por: Joly, F, et al.
Publicado: (2000)

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005)

Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
por: Hind, D, et al.
Publicado: (2007)

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen
por: Jansen, Maurice P.H.M., et al.
Publicado: (2016)

Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
por: Park, Y, et al.
Publicado: (2009)

A high incidence of vertebral fracture in women with breast cancer
por: Kanis, J A, et al.
Publicado: (1999)

Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer
por: Paradiso, A, et al.
Publicado: (2001)

Lithium and Tamoxifen Modulate Behavior and Protein Kinase C Activity in the Animal Model of Mania Induced by Ouabain
por: Valvassori, Samira S, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_35pfdb1g40sas9mqc3ooldf467